Equity · Healthcare
IONS
NASDAQIonis Pharmaceuticals (IONS)
The line runs 62 USD on 24 August through 26.61 USD on 20 November, on a scale from 20 to 80. Days the market did not trade hold the previous close, flat.
- Market cap
- 4.4B USD
- Revenue, year to Dec 2025
- 943.7M USD
- EPS, diluted, year to Dec 2025
- −2.38 USD
- 52-week range
- 26.61 USD – 86.52 USD
- Avg volume
- 245.7K
- Mentions, 30 days
- 2
as of Nov 20, 2026
Have Ionis Pharmaceuticals (IONS) insiders bought or sold shares recently?
In the 90 days to 23 Nov 2026, Ionis Pharmaceuticals insiders reported 2 open-market sales and 1 purchase (SEC Form 4).
Form 4, 90 days to 23 Nov 2026, newest reported trade 10 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Nov 2026 | Hayden Michael RDirector | Buy | 5,000 | 148K USD |
| 16 Oct 2026 | Devers Shannon L.EVP, Chief Human Resources Ofc | Sell | 1,357 | 59K USD |
| 16 Oct 2026 | Swayze EricEVP Research | Sell | 53 | 2K USD |
| Bought | 1 open-market purchase | 5,000 | $148K | |
| Sold | 2 open-market sales | 1,410 | $61K |
6 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Oct 2026 | Devers Shannon L.EVP, Chief Human Resources Ofc | Option exercise | 2,820 | |
| 15 Oct 2026 | Swayze EricEVP Research | Option exercise | 125 | |
| 31 Aug 2026 | BENNETT C FRANKEVP, Chief Scientific Officer | Other | 110 | 6K USD |
| 31 Aug 2026 | O'NEIL PATRICK R.EVP CLO & General Counsel | Other | 63 | 3K USD |
| 31 Aug 2026 | Monia Brett PChief Executive Officer | Other | 98 | 5K USD |
| 31 Aug 2026 | Birchler BrianEVP, Corp and Development Ops | Other | 58 | 3K USD |
Which funds hold Ionis Pharmaceuticals (IONS)?
14 of the 45 institutional funds we track reported a Ionis Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 725.2M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Held (±25%) | 6,727,410 | 300.4M USD | +7.6% |
| Citadel Advisors | Added | 4,026,275 | 179.8M USD | +1,604.0% |
| Point72 Asset Management | New position | 1,227,788 | 54.8M USD | |
| Baker Bros. Advisors | Trimmed | 1,023,864 | 45.7M USD | −50.0% |
| ARK Investment Management | Added | 923,162 | 41.2M USD | +206.9% |
| Millennium Management | Added | 750,785 | 33.5M USD | +159.9% |
| D. E. Shaw & Co. | Added | 543,130 | 24.3M USD | +82.8% |
| Renaissance Technologies | Trimmed | 354,214 | 15.8M USD | −36.7% |
| Balyasny Asset Management | New position | 298,828 | 13.3M USD | |
| Fisher Asset Management | Added | 182,997 | 8.2M USD | +33.4% |
Showing the 10 largest of 14 reported positions. The figures above count all of them.
Have members of Congress traded Ionis Pharmaceuticals (IONS)?
The most recent congressional trade disclosed in Ionis Pharmaceuticals is a sale by Daniel S. Goldman (house, NY), dated 06 Mar 2023.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 06 Mar 2023 | Daniel S. Goldmanhouse · Democrat–NY | Sale | 1K USD–15K USD | 42 days |
What has been filed or recorded for Ionis Pharmaceuticals (IONS)?
The filings we hold for Ionis Pharmaceuticals, newest first: 3 fails-to-deliver days, 7 quarterly earnings reports, 1 annual report and 5 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 879 shares | 38K USD notional · 0.001% of shares out |
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 19,578 shares | 869K USD notional · 0.012% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 14,082 shares | 610K USD notional · 0.008% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.66 USD | |
| 30 Sep 2026 | Financials | Total assets | 2.9B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 393.6M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.69 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.56 USD | |
| 31 Dec 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.70 USD | |
| 31 Dec 2025 | Financials | Revenue | 943.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −381.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.38 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.80 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.70 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.93 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.66 USD | Revenue $227M |
What is Reddit saying about Ionis Pharmaceuticals (IONS)?
Reddit mentioned IONS 2 times in the 30 days to 22 November 2026, across 2 of the communities we track. All of them were scored for sentiment: 50% read bullish, 0% bearish and 50% neither. Reddit data updated 22 November 2026.
30-day window, Method
How do Reddit mentions of Ionis Pharmaceuticals (IONS) compare with its price?
Share ↗
Which subreddits are talking about Ionis Pharmaceuticals (IONS)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/stocks | 50% | 1 | −0.01 |
| r/wallstreetbets | 50% | 1 | +0.09 |
What do people ask about Ionis Pharmaceuticals (IONS)?
What did Ionis Pharmaceuticals shares close at?26.61
Ionis Pharmaceuticals closed at 26.61 USD on 20 Nov 2026, down 2.31% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Ionis Pharmaceuticals’ market cap?4.4B
Ionis Pharmaceuticals is worth 4.4B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Ionis Pharmaceuticals’ revenue?943.7M
Ionis Pharmaceuticals reported revenue of 943.7M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Ionis Pharmaceuticals insiders bought or sold shares recently?2 sales
In the 90 days to 23 Nov 2026, Ionis Pharmaceuticals insiders reported 2 open-market sales and 1 purchase (SEC Form 4). A further 6 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Ionis Pharmaceuticals?14 of 45
14 of the 45 funds we track reported a Ionis Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Citadel Advisors and Point72 Asset Management. See Funds
Have members of Congress traded Ionis Pharmaceuticals?1 trade
Yes. 1 trade in Ionis Pharmaceuticals appears in the congressional disclosures we hold: a sale by Daniel S. Goldman (House, NY) dated 6 Mar 2023, filed 17 Apr 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Ionis Pharmaceuticals last report earnings?−0.66
Ionis Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.66 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Ionis Pharmaceuticals?0 mentions
Ionis Pharmaceuticals was mentioned 0 times in the last 7 days across the finance subreddits we track, and 2 times over the trailing 30 days. Of the 2 mentions scored for sentiment, 50% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Daniel S. Goldman: US House, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words